Maywufa Company Ltd. (1731.TW)
TWD 21.9
(1.62%)
TWD 21.9
(1.62%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 794.91 Million TWD | 49.16% |
| 2022 | 532.91 Million TWD | -22.38% |
| 2021 | 686.53 Million TWD | 14.38% |
| 2020 | 600.21 Million TWD | -38.61% |
| 2019 | 977.7 Million TWD | 2.54% |
| 2018 | 953.45 Million TWD | 6.7% |
| 2017 | 893.59 Million TWD | 2.5% |
| 2016 | 871.78 Million TWD | -3.05% |
| 2015 | 899.24 Million TWD | 12.86% |
| 2014 | 796.74 Million TWD | -9.16% |
| 2013 | 877.11 Million TWD | 6.04% |
| 2012 | 827.14 Million TWD | 2.4% |
| 2011 | 807.74 Million TWD | -31.87% |
| 2010 | 1.18 Billion TWD | 2.45% |
| 2009 | 1.15 Billion TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.11 Billion TWD | 19.81% |
| 2024 Q1 | 930 Million TWD | 16.99% |
| 2023 FY | 794.91 Million TWD | 49.16% |
| 2023 Q1 | 619.77 Million TWD | 16.3% |
| 2023 Q2 | 777.92 Million TWD | 25.52% |
| 2023 Q4 | 794.91 Million TWD | 4.87% |
| 2023 Q3 | 758.02 Million TWD | -2.56% |
| 2022 Q3 | 429.81 Million TWD | -7.38% |
| 2022 Q2 | 464.04 Million TWD | -27.36% |
| 2022 FY | 532.91 Million TWD | -22.38% |
| 2022 Q4 | 532.91 Million TWD | 23.99% |
| 2022 Q1 | 638.79 Million TWD | -6.95% |
| 2021 Q1 | 610.54 Million TWD | 1.72% |
| 2021 FY | 686.53 Million TWD | 14.38% |
| 2021 Q2 | 634.63 Million TWD | 3.95% |
| 2021 Q4 | 686.53 Million TWD | 5.6% |
| 2021 Q3 | 650.11 Million TWD | 2.44% |
| 2020 FY | 600.21 Million TWD | -38.61% |
| 2020 Q1 | 566.96 Million TWD | -42.01% |
| 2020 Q2 | 641.68 Million TWD | 13.18% |
| 2020 Q3 | 600.39 Million TWD | -6.43% |
| 2020 Q4 | 600.21 Million TWD | -0.03% |
| 2019 Q1 | 910.38 Million TWD | -4.52% |
| 2019 FY | 977.7 Million TWD | 2.54% |
| 2019 Q2 | 1.04 Billion TWD | 14.36% |
| 2019 Q4 | 977.7 Million TWD | 3.67% |
| 2019 Q3 | 943.07 Million TWD | -9.42% |
| 2018 Q4 | 953.45 Million TWD | -4.46% |
| 2018 Q1 | 1.03 Billion TWD | 15.79% |
| 2018 Q2 | 1.11 Billion TWD | 8.1% |
| 2018 Q3 | 997.98 Million TWD | -10.77% |
| 2018 FY | 953.45 Million TWD | 6.7% |
| 2017 Q1 | 829.39 Million TWD | -4.86% |
| 2017 FY | 893.59 Million TWD | 2.5% |
| 2017 Q4 | 893.59 Million TWD | -2.04% |
| 2017 Q3 | 912.21 Million TWD | -3.81% |
| 2017 Q2 | 948.32 Million TWD | 14.34% |
| 2016 Q2 | 881.98 Million TWD | 9.23% |
| 2016 Q1 | 807.42 Million TWD | -10.21% |
| 2016 FY | 871.78 Million TWD | -3.05% |
| 2016 Q4 | 871.78 Million TWD | 5.82% |
| 2016 Q3 | 823.81 Million TWD | -6.6% |
| 2015 Q4 | 899.24 Million TWD | 1.54% |
| 2015 FY | 899.24 Million TWD | 12.86% |
| 2015 Q2 | 915.31 Million TWD | 10.51% |
| 2015 Q3 | 885.63 Million TWD | -3.24% |
| 2015 Q1 | 828.25 Million TWD | 3.95% |
| 2014 Q3 | 775.33 Million TWD | -12.99% |
| 2014 Q2 | 891.09 Million TWD | -2.89% |
| 2014 FY | 796.74 Million TWD | -9.16% |
| 2014 Q1 | 917.64 Million TWD | 4.62% |
| 2014 Q4 | 796.74 Million TWD | 2.76% |
| 2013 Q3 | 950.05 Million TWD | 3.7% |
| 2013 Q4 | 877.11 Million TWD | -7.68% |
| 2013 FY | 877.11 Million TWD | 6.04% |
| 2013 Q1 | 795.96 Million TWD | -3.77% |
| 2013 Q2 | 916.16 Million TWD | 15.1% |
| 2012 Q1 | 782.87 Million TWD | -3.08% |
| 2012 Q3 | 784.98 Million TWD | -8.36% |
| 2012 Q4 | 827.14 Million TWD | 5.37% |
| 2012 FY | 827.14 Million TWD | 2.4% |
| 2012 Q2 | 856.57 Million TWD | 9.41% |
| 2011 Q4 | 807.74 Million TWD | -4.27% |
| 2011 FY | 807.74 Million TWD | -31.87% |
| 2011 Q1 | 898.88 Million TWD | -24.18% |
| 2011 Q3 | 843.77 Million TWD | -8.92% |
| 2011 Q2 | 926.36 Million TWD | 3.06% |
| 2010 Q4 | 1.18 Billion TWD | 0.0% |
| 2010 FY | 1.18 Billion TWD | 2.45% |
| 2009 FY | 1.15 Billion TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grape King Bio Ltd | 3.88 Billion TWD | 79.523% |
| Standard Chem & Pharm CO., LTD. | 3.05 Billion TWD | 73.949% |
| ScinoPharm Taiwan, Ltd. | 1.35 Billion TWD | 41.428% |
| Lotus Pharmaceutical Co., Ltd. | 15.65 Billion TWD | 94.923% |
| LIWANLI Innovation Co., Ltd. | 50.66 Million TWD | -1469.118% |
| YungShin Global Holding Corporation | 3.59 Billion TWD | 77.904% |
| PhytoHealth Corporation | 79.84 Million TWD | -895.523% |
| SCI Pharmtech, Inc. | 1.59 Billion TWD | 50.03% |
| Formosa Laboratories, Inc. | 5.42 Billion TWD | 85.35% |
| PharmaEssentia Corporation | 3.32 Billion TWD | 76.065% |
| Bora Pharmaceuticals Co., LTD. | 13.28 Billion TWD | 94.017% |